A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Inclusion Criteria: 1. Sign the written informed consent; 2. Aged ≥ 18 and ≤ 70 years old; 3. Confirmed recurrent and metastatic triple negative breast cancer by imaging and pathology (ER negative (IHC ER positive percentage \< 1%), PR negative (IHC PR positive percentage \< 1%), HER2 negative (IHC -/+or IHC++but FISH/CISH -)), at least one measurable focus meeting the RECIST v1.1 standard; 4. Untreated local recurrence of unresectable TNBC or untreated distant metastasis of TNBC 5. Must be able to swallow tablets; 6. Clarify the positive status of PD-L1 expression and CPS score ≥ 1 7. ECOG score: 0 to 1; 8. Expected survival period ≥ 12 weeks; 9. The results of patient's blood tests are as follows (excluding the use of any blood components and cell growth factors during screening): * Absolute neutrophil count ≥ 1.5 × 109/L; * Platelets ≥ 100 × 109/L; * Hemoglobin ≥ 9g/dL; * Serum albumin ≥ 3g/dL; * Thyroid stimulating hormone (TSH) ≤ ULN (if abnormal, T3 and T4 levels should be examined simultaneously. If T3 and T4 levels are normal, they can be included in the group); * Bilirubin ≤ 1.0 times ULN (Gilbert's syndrome or liver metastasis subject total bilirubin ≤ 1.5 times ULN); * ALT and AST ≤ 1.5 times ULN (liver metastasis subjects ≤ 3 times ULN); * AKP ≤ 2.5 times ULN; * Renal function within 7 days before the first administration: serum creatinine ≤ 1.5 times ULN or creatinine clearance rate ≥ 60mL/min (using the standard Cockcroft Gault formula, see Appendix 3); 10. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment. 11. Left ventricular ejection fraction ≥ 50% Exclusion Criteria: 1. Received other interventional clinical trials within 28 days before the first dose; 2. Failure to recover from adverse reactions of previous treatment 3. Neurological disorders of grade ≥ 2 4. Untreated active brain metastases or meningeal metastases 5. Previously received nab-paclitaxel neoadjuvant therapy or adjuvant therapy and experienced local recurrence or distant metastasis within 12 months; 6. Has experienced severe allergic reactions to other monoclonal antibodies; 7. Received other anti-tumor treatments within 28 days before the first administration; 8. Suffering from hypertension and unable to achieve good control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg); 9. Received antibody or T cell co stimulatory therapy such as PD-1, PD-L1, PD-L2, CTLA-4, Tim3, LAG3, etc; 10. Special genetic diseases (including rare galactose intolerance, primary lactase deficiency, or glucose galactose malabsorption); 11. Active autoimmune disease or history of autoimmune disease (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or complete remission of childhood asthma without any intervention in adulthood may be included; subjects with asthma requiring medical intervention with bronchodilators may not be included); 12. Heart diseases, such as: * NYHA grade 2 or above heart failure * Unstable angina pectoris * Have experienced a myocardial infarction within the past year * Clinically significant supraventricular or ventricular arrhythmias require treatment or intervention； 13. Urine protein level is ≥++, or the 24-hour urine protein level is ≥ 1.0 g; 14. Known genetic or acquired bleeding and thrombophilia tendencies (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, splenomegaly, etc.); 15. Have a history of tuberculosis; 16. Active period of HBV or HCV, and other active infectious diseases; 17. Had or is currently experiencing qualitative pneumonia or requires steroid treatment for pneumonia; 18. Congenital or acquired immune dysfunction (such as HIV infected individuals); 19. Received or about to receive a live vaccine within 4 weeks prior to the study or possibly during the study period; 20. Allergic or contraindicated to the experimental drug.